{"id":"NCT02777931","sponsor":"Aevi Genomic Medicine, LLC, a Cerecor company","briefTitle":"Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD","officialTitle":"A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-06","primaryCompletion":"2017-02-10","completion":"2017-02-17","firstPosted":"2016-05-19","resultsPosted":"2018-03-29","lastUpdate":"2021-08-11"},"enrollment":101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Disorder With Hyperactivity"],"interventions":[{"type":"DRUG","name":"NFC-1","otherNames":["NFC1"]},{"type":"DRUG","name":"Placebo","otherNames":["Control"]}],"arms":[{"label":"NFC-1","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.","primaryOutcome":{"measure":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale, Version 5 (ADHD-RS-5) Total Score","timeFrame":"Baseline to Visit 8 (Week 6)","effectByArm":[{"arm":"NFC-1","deltaMin":-14.2,"sd":1.82},{"arm":"Placebo","deltaMin":-12.1,"sd":1.75}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37120522","35690720"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["Fatigue","Weight increase","Headache","Accidental overdose","Nausea"]}}